Abstract
Checkpoint inhibitors like anti-PD1/PD-L1 have demonstrated significant therapeutic efficacy in a subset of patients partly through reinvigoration of CD8 T cells. However, their impact on myeloid cells remains largely unknown. Here, we report that anti-PD-L1 treatment favorably impacts the phenotype and function of tumor macrophages by polarizing the macrophage compartment toward a more proinflammatory phenotype. This phenotype was characterized by a decrease in Arginase-I (ARG1) expression and an increase in iNOS, MHCII, and CD40 expression. Whole-transcriptome profiling further confirmed extensive polarization of both tumor monocytes and macrophages from a suppressive to a proinflammatory, immunostimulatory phenotype. This polarization was driven mainly through IFNγ and was associated with enhanced T-cell activity. Transfer of monocytes into anti-PD-L1-treated tumor-bearing mice led to macrophage differentiation into a more proinflammatory phenotype, with an increase in CD8 T cells expressing granzyme-B and an increase in the CD8/Treg ratio compared with control-treated mice. Although in responsive tumor models, anti-PD-L1 treatment remodeled the macrophage compartment with beneficial effects on T cells, both macrophage reprogramming and depletion were needed to maximize anti-PD-L1 responses in a tumor immune contexture with high macrophage burden. Our results demonstrate that anti-PD-L1 treatment can favorably remodel the macrophage compartment in responsive tumor models toward a more proinflammatory phenotype, mainly through increased IFNγ levels. They also suggest that directly targeting these cells with reprogramming and depleting agents may further augment the breadth and depth of response to anti-PD-L1 treatment in less responsive or more macrophage-dense tumor microenvironments. SIGNIFICANCE: This work demonstrates that increased IFNγ signaling following anti-PD-L1 treatment can remodel the macrophage compartment to enhance T-cell responses.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/7/1493/F1.large.jpg.
Highlights
Tumor-associated macrophages (TAM) are abundantly found in tumors and contribute critically to the immune set point [1,2,3]
Our results demonstrate that anti–PD-L1 treatment can favorably remodel the macrophage compartment in responsive tumor models toward a more proinflammatory phenotype, mainly through increased
Tumor macrophages have a suppressive phenotype that correlates with tumor burden To investigate the effects of aPDL1 treatment on TAMs, we first focused on the baseline characteristics of the myeloid compartment in the MC38 tumor model given its partial responsiveness to treatment and its significant macrophage infiltration
Summary
Tumor-associated macrophages (TAM) are abundantly found in tumors and contribute critically to the immune set point [1,2,3]. Fcg receptors and IL1b have been reported to be involved in phagocytosis-induced PDL1 and IDO expression [10], and iNOS has been shown to play both anti- and protumoral roles [11,12,13] despite continuing to serve as a common M1-associated marker [14,15,16]. These results highlight the necessity to examine the expression of multiple markers and to integrate whole transcriptome analysis for a more accurate evaluation of macrophage functional state
Submitted Version (Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have